Search #ABSTRACT#
Dey, L.P. Granted Patent for AccuNeb®, Pediatric Asthma Medication
Napa, CA, March 16, 2004 - Dey, L.P., a specialty pharmaceutical company focused on prescription drug products for the treatment of selected respiratory diseases and allergies, has announced that effective March 9, 2004, the U.S. Patent and Trademark Office (USPTO) has issued a patent covering AccuNeb®. AccuNeb® is the only FDA-approved lower-concentration, unit-dose albuterol sulfate approved for the treatment of asthma in children aged two to twelve. AccuNeb® was developed by Dey, L.P.
“Dey is highly gratified by the USPTO’s granting of this patent for AccuNeb®, the only FDA-approved lower concentration unit-dose formulation of albuterol for children as young as two years of age,” said J. Melville Engle, President and Chief Executive Officer of Dey, L.P. “This patent, our second for a product developed in-house and promoted by our own sales force, reinforces the strength of our development program and our intellectual property portfolio. AccuNeb® provides clear clinical benefit to very young children, delivering effective, fast-acting relief from asthma in a lower concentration dose that greatly reduces the likelihood and severity of side effects.“
About Dey, L.P.
Dey, L.P., is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases and respiratory-related allergies. Since 1978, patients have benefited from Dey's commitment to innovative and affordable health care solutions.The Web sites for DEY include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.duoneb.com and www.epipen.com. Dey is an affiliate of EMD, Inc., a division of Merck KGaA, Darmstadt, Germany.
###
Contact: Dey, L.P. Media Line 1-800-755-5560 ext. 8363
OR
Jennifer Paganelli, Feinstein Kean Healthcare, 212-880-5263
